U.S. pharmacists will now be able to automatically substitute a cheaper biosimilar for a more expensive brand-name insulin, the U.S Food and Drug Administration announced Wednesday. The agency’s approval of an “interchangeable” biosimilar could save diabetics and health plans millions each year, the Associated Press reported. Until now, doctors have had to specifically prescribe a… read on > read on >










-300x200.jpeg)








